Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia A.M.; Scheiner, Bernhard; D’Alessio, Antonio; Manfredi, Giulia F.; Nishida, Naoshi; Ang, Celina; Marron, Thomas U.; Saeed, Anwaar; Wietharn, Brooke; Pinter, Matthias; Cheon, Jaekyung; Huang, Yi-Hsiang; Lee, Pei-Chang; Phen, Samuel; Gampa, Anuhya; Pillai, Anjana; Vivaldi, Caterina; Salani, Francesca; Masi, Gianluca; Roehlen, Natascha; Thimme, Robert; Vogel, Arndt; Schönlein, Martin; von Felden, Johann; Schulze, Kornelius; Wege, Henning; Galle, Peter R.; Kudo, Masatoshi; Rimassa, Lorenza; Singal, Amit G.; El Tomb, Paul; Ulahannan, Susanna; Parisi, Alessandro; Chon, Hong Jae; Hsu, Wei-Fan; Stefanini, Bernardo; Verzoni, Elena; Giusti, Raffaele; Veccia, Antonello; Catino, Annamaria; Aprile, Giuseppe; Guglielmini, Pamela Francesca; Di Napoli, Marilena; Ermacora, Paola; Antonuzzo, Lorenzo; Rossi, Ernesto; Verderame, Francesco; Zustovich, Fable; Ficorella, Corrado; Di Pietro, Francesca Romana; Battelli, Nicola; Negrini, Giorgia; Grossi, Francesco; Bordonaro, Roberto; Pipitone, Stefania; Banzi, Maria; Ricciardi, Serena; Laera, Letizia; Russo, Antonio; De Giorgi, Ugo; Cavanna, Luigi; Sorarù, Mariella; Montesarchio, Vincenzo; Bordi, Paola; Brunetti, Leonardo; Pinto, Carmine; Bersanelli, Melissa; Cammà, Calogero; Cortellini, Alessio; Pinato, David J.

doi:10.1016/j.jhep.2023.10.040

Cited by 4 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with non-HCC malignancies, liver injury related to ICIs is more common in patients with HCC. However, the outcomes in terms of the requirement of corticosteroid therapy, hepatic decompensation, treatment discontinuation, and overall survival are similar [84]. A retrospective case series of patients with advanced HCC and Child Pugh B cirrhosis treated with Nivolumab showed high rates of adverse events mainly associated with liver dysfunction and advanced tumor burden.…”

Section: Effect Of Icis On Portal Hypertensionmentioning

confidence: 99%

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

De Gaetano,

Pallozzi,

Cerrito

et al. 2024

Cancers

View full text Add to dashboard Cite

The management of CSPH in patients undergoing systemic treatment for HCC has emerged as a critical concern due to the absence of reliable diagnostic criteria and uncertainties surrounding therapeutic approaches. This review aims to underscore the primary pathophysiological aspects linking HCC and PH, while also addressing the current and emerging clinical strategies for the management of portal hypertension. A review of studies from January 2003 to June 2023 was conducted using the PubMed database and employing MeSH terms, such as “hepatocellular carcinoma”, “immune checkpoint inhibitors”, “systemic therapy”, “portal hypertension”, “variceal bleeding” and “tyrosine kinase inhibitors”. Despite promising results of tyrosine kinase inhibitors in animal models for PH and fibrosis, only Sorafenib has demonstrated similar effects in human studies, whereas Lenvatinib appears to promote PH development. The impact of Atezolizumab/Bevacizumab on PH remains uncertain, with an increasing risk of bleeding related to Bevacizumab in patients with prior variceal hemorrhage. Given the absence of specific guidelines, endoscopic surveillance during treatment is advisable, and primary and secondary prophylaxis of variceal bleeding should adhere to the Baveno VII recommendations. Furthermore, in patients with advanced HCC, refinement of diagnostic criteria for CSPH and guidelines for its surveillance are warranted.

show abstract

Section: Effect Of Icis On Portal Hypertensionmentioning

confidence: 99%